Troriluzole - Biohaven Pharmaceuticals
Alternative Names: BHV-4157; BHV-4157a; Dazluma; FC 4157; trigriluzole; Trigriluzole-Biohaven Pharmaceuticals; Troriluzole-hydrochlorideLatest Information Update: 21 Aug 2024
At a glance
- Originator Yale University
- Developer Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals; Global Coalition for Adaptive Research; National Cancer Institute (USA); Rutgers Cancer Institute of New Jersey
- Class Acetamides; Amines; Antidementias; Antineoplastics; Anxiolytics; Behavioural disorder therapies; Benzothiazoles; Fluorinated hydrocarbons; Neuroprotectants; Peptides; Small molecules
- Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Spinocerebellar degeneration
- Phase III Obsessive-compulsive disorders
- Phase II/III Alzheimer's disease; Glioblastoma
- Phase II Malignant melanoma
- No development reported Lymphoma; Solid tumours
- Discontinued Anxiety disorders
Most Recent Events
- 21 Aug 2024 Dana-Farber Cancer Institute plans a phase 0 (Early phase I) trial for Glioblastoma in USA (PO, Capsule) in February 2025 (NCT06552260)
- 13 Apr 2024 Pharmacokinetics data from a phase I trial presented at 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
- 13 Apr 2024 Biohaven Pharmaceuticals initiates a phase I pharmacokinetics trial prior to April 2024